Reuters logo
a month ago
BRIEF-Oncomed says GSK terminates license agreement with company
July 10, 2017 / 8:42 PM / a month ago

BRIEF-Oncomed says GSK terminates license agreement with company

July 10 (Reuters) - Glaxosmithkline Plc

* Oncomed Pharmaceuticals Inc - on July 7, received a letter, dated June 30, 2017 from Glaxosmithkline LLC- SEC filing

* Oncomed Pharmaceuticals Inc - GSK terminating research and development collaboration, option, and license agreement by and between company and GSK

* Oncomed Pharma - GSK indicated it was terminating agreement because had decided not to exercise option for Tarextumab (anti-notch2/3, OMP-59R5)

* Oncomed Pharmaceuticals Inc - Termination will become effective on date that is 120 days after date of termination letter

* Oncomed Pharmaceuticals Inc - no early termination penalties will be incurred by company as a result of termination of agreement Source: (bit.ly/2uaZS8k) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below